These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1148 related items for PubMed ID: 19514084

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.
    J Clin Oncol; 2008 May 01; 26(13):2192-7. PubMed ID: 18445844
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M.
    J Clin Oncol; 2006 Sep 20; 24(27):4412-7. PubMed ID: 16983109
    [Abstract] [Full Text] [Related]

  • 4. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.
    Br J Neurosurg; 2013 Dec 20; 27(6):772-8. PubMed ID: 23662801
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.
    N Engl J Med; 2005 Mar 10; 352(10):997-1003. PubMed ID: 15758010
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
    Lam N, Chambers CR.
    J Oncol Pharm Pract; 2012 Jun 10; 18(2):229-38. PubMed ID: 22065199
    [Abstract] [Full Text] [Related]

  • 9. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):670-6. PubMed ID: 19836157
    [Abstract] [Full Text] [Related]

  • 10. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, Goel A.
    Br J Neurosurg; 2007 Dec 01; 21(6):583-7. PubMed ID: 18071985
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.
    Clin Neurol Neurosurg; 2015 May 01; 132():1-8. PubMed ID: 25723791
    [Abstract] [Full Text] [Related]

  • 12. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W, DIRECTOR Study Group.
    Clin Cancer Res; 2015 May 01; 21(9):2057-64. PubMed ID: 25655102
    [Abstract] [Full Text] [Related]

  • 13. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
    Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP.
    J Clin Oncol; 2013 Nov 10; 31(32):4085-91. PubMed ID: 24101040
    [Abstract] [Full Text] [Related]

  • 14. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM.
    Radiother Oncol; 2010 Dec 10; 97(3):377-81. PubMed ID: 20855119
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY.
    J Clin Oncol; 2011 Aug 01; 29(22):3050-5. PubMed ID: 21709196
    [Abstract] [Full Text] [Related]

  • 17. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.
    J Clin Oncol; 2010 Jun 01; 28(16):2712-8. PubMed ID: 20439646
    [Abstract] [Full Text] [Related]

  • 18. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
    Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D.
    J Clin Oncol; 2007 Apr 20; 25(12):1470-5. PubMed ID: 17442989
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, Kim ST, Lim DH, Kim WS, Nam DH.
    Clin Neurol Neurosurg; 2009 Oct 20; 111(8):679-82. PubMed ID: 19640635
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.